 |
Video: What is a Stock Split?
|
 |
Titan Pharmaceuticals is a pharmaceutical company developing therapeutics utilizing its drug delivery platform, ProNeura, for the treatment of select chronic diseases. Probuphine is a product based on its ProNeura technology approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder (OUD). Co. is conducting non-clinical studies with a nalmefene implant for the potential treatment of OUD under a grant from the National Institutes of Health. Co. is collaborating with the Walter Reed Army Institute of Research and South West Research Institute in the early non-clinical evaluation of the ProNeura platform in malaria prophylaxis. According to our TTNP split history records, Titan Pharmaceuticals has had 2 splits. | |
 |

Titan Pharmaceuticals (TTNP) has 2 splits in our TTNP split history database. The first split for TTNP took place on January 25, 2019. This was a 1 for 6 reverse split, meaning for each 6 shares of TTNP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 166.666666666667 share position following the split. TTNP's second split took place on December 01, 2020. This was a 1 for 30 reverse split, meaning for each 30 shares of TTNP owned pre-split, the shareholder now owned 1 share. For example, a 166.666666666667 share position pre-split, became a 5.55555555555556 share position following the split.
When a company such as Titan Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TTNP split history from start to finish, an original position size of 1000 shares would have turned into 5.55555555555556 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Titan Pharmaceuticals shares, starting with a $10,000 purchase of TTNP, presented on a split-history-adjusted basis factoring in the complete TTNP split history.

Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
03/27/2013 |
|
End date: |
03/24/2023 |
|
Start price/share: |
$304.20 |
|
End price/share: |
$0.75 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.75% |
|
Average Annual Total Return: |
-45.16% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$24.64 |
|
Years: |
10.00 |
|
|
 |
Date |
Ratio |
01/25/2019 | 1 for 6 | 12/01/2020 | 1 for 30 |
|
 |